NCT03555292

11C-PIB PET/CT in Patients With Parkinson's Disease and Parkinsonian Dementia Syndromes

Safety and Diagnostic Performance of 11C-PIB PET/CT in Patients With Parkinson's Disease and Parkinsonian Dementia Syndromes

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 200 (estimated)
• Sponsor: Oriental Neurosurgery Evidence-Based-Study Team · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

To evaluate the potential contribution of amyloid burden, as indexed by 11C-Pittsburgh compound B (PiB) retention, to the progression of cognitive impairments in patients with Parkinson's disease(PD).

Detailed description

Study design: Multi-center, Five-arm Subjects: Patients with PD without dementia; Patients with PD with mild cognitive impairment (MCI); Patients with PD with dementia; Patients with a dementia with Lewy bodies(DLB); Healthy person Sample size: 200, including a PD without dementia group of 75 patients, a PD with MCI group of 30 patients, a PD with dementia group of 20 patients, a DLB group of 25 patients and a normal control group of 50 subjects.

Conditions

• Parkinson Disease

Interventions

Type	Name	Description
DRUG	11C-PiB	11C-PIB with 555MBq were intravenously injected into the patients immediately before the PET/CT scans

Timeline

• Start date: 2017-07-12
• Primary completion: 2021-05-12
• Completion: 2021-10-12
• First posted: 2018-06-13
• Last updated: 2018-06-13

Locations

3 sites across 1 country: China